Mobile

Efficacy and Safety of REGN727 added-on to Rosuvastatin versus Ezetimibe added-on to Rosuvastatin versus Rosuvastatin dose increase in patients who are not controlled on Rosuvastatin

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002333-11

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the reduction of LDL-C by REGN727 as add-on therapy to rosuvastatin in comparison with EZE as add-on therapy to rosuvastatin, and in comparison with doubling the rosuvastatin dose, after 24 weeks of treatment in patients with hypercholesterolemia at high CV risk.

Critère d'inclusion

  • Patients with Non-familial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) at high CV risk who are not adequately controlled with rosuvastatin (10mg or 20mg) with or without other lipid-modifying therapy (LMT) (excluding EZE)

Liens